Reuters logo
in 2 months
BRIEF-Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis
May 17, 2017 / 8:11 PM / in 2 months

BRIEF-Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis

1 Min Read

May 17 (Reuters) - Aurinia Pharmaceuticals Inc

* Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis

* Aurinia Pharmaceuticals - Trial to recruit 320 patients, intended to support full marketing approval of voclosporin for patients with LN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below